Rallybio (RLYB) Return on Capital Employed (2021 - 2026)
Rallybio (RLYB) posted Return on Capital Employed of 59.25% for Q1 2026, down 8.83% sequentially from 54.44% in Q4 2025, and up 2595.0% YoY from 2.2% in Q1 2025.
Rallybio (RLYB) Return on Capital Employed (2021 - 2026) Analysis & Trends
Rallybio has reported Return on Capital Employed for 6 years, with the latest figure at 59.25% in Q1 2026.
- Quarterly Return on Capital Employed rose 2595.0% year-over-year to 59.25% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 59.25% (up 2595.0% YoY) and the FY2025 annual result came in at 54.24%, up 1642.0% from the prior year.
- Return on Capital Employed fell to 59.25% in Q1 2026 per RLYB's latest filing, from 54.44% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 27.74% in Q1 2022 and troughed at 92.31% in Q2 2024.
- A 5-year average of 63.8% and a median of 59.25% in 2026 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed slumped 4166 bps in 2024, then soared 3543 bps in 2025.
- Over 5 years, Return on Capital Employed stood at 44.87% in 2022, then plunged by 53 bps to 68.55% in 2023, then tumbled by 31 bps to 89.87% in 2024, then soared by 39 bps to 54.44% in 2025, then retreated by 9 bps to 59.25% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 59.25%, 54.44%, and 69.8% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Rallybio | 94.61 Mn | 94.61 Mn | - | -38.13% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -38.13% |
| Mar 31, 2026 | -59.25% |
| Dec 31, 2025 | -54.44% |
| Sep 30, 2025 | -69.80% |
| Jun 30, 2025 | -87.76% |
| Mar 31, 2025 | -85.19% |
| Dec 31, 2024 | -89.87% |
| Sep 30, 2024 | -90.29% |
| Jun 30, 2024 | -92.31% |
| Mar 31, 2024 | -82.49% |
| Dec 31, 2023 | -68.55% |
| Sep 30, 2023 | -57.19% |
| Jun 30, 2023 | -50.65% |
| Mar 31, 2023 | -43.71% |
| Dec 31, 2022 | -44.87% |
| Sep 30, 2022 | -45.62% |
| Jun 30, 2022 | -34.94% |
| Mar 31, 2022 | -27.74% |
| Dec 31, 2021 | -25.15% |
| Sep 30, 2021 | -29.02% |